GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiromic BioPharma Inc (OTCPK:KRBP) » Definitions » Cash-to-Debt

Kiromic BioPharma (Kiromic BioPharma) Cash-to-Debt : 0.27 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kiromic BioPharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Kiromic BioPharma's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.27.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Kiromic BioPharma couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Kiromic BioPharma's Cash-to-Debt or its related term are showing as below:

KRBP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07   Med: 6.02   Max: No Debt
Current: 0.27

During the past 6 years, Kiromic BioPharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.07. And the median was 6.02.

KRBP's Cash-to-Debt is ranked worse than
90.15% of 1492 companies
in the Biotechnology industry
Industry Median: 6.85 vs KRBP: 0.27

Kiromic BioPharma Cash-to-Debt Historical Data

The historical data trend for Kiromic BioPharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Kiromic BioPharma Cash-to-Debt Chart

Kiromic BioPharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial No Debt 21.69 55.72 0.07 0.21

Kiromic BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.27 0.39 0.21 0.27

Competitive Comparison of Kiromic BioPharma's Cash-to-Debt

For the Biotechnology subindustry, Kiromic BioPharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiromic BioPharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiromic BioPharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Kiromic BioPharma's Cash-to-Debt falls into.



Kiromic BioPharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Kiromic BioPharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Kiromic BioPharma's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiromic BioPharma  (OTCPK:KRBP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Kiromic BioPharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Kiromic BioPharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiromic BioPharma (Kiromic BioPharma) Business Description

Traded in Other Exchanges
N/A
Address
7707 Fannin Street, Suite 140, Houston, TX, USA, 77054
Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.
Executives
Brian Hungerford officer: CFO 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Pamela Misajon director 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Michael Catlin director 7707 FANNIN ST, SUITE 140, HOUSTON TX 77054
Karen Reeves director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Francis X Tirelli director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Daniel Grant Clark officer: Interim CFO 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Internati Maurizio Chiriva director, officer: Chairman, CEO, and President 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Michael Charles Ryan officer: Chief Technology Officer 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Ignacio Nunez officer: See Remarks 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Jerry A. Schneider director ONE VISION DRIVE, NATICK MA 01760
Michael Nagel director C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Pietro Bersani director C/O FUEL SYSTEMS SOLUTIONS, INC., 780 THIRD AVE. 25TH FLOOR, NEW YORK NY 10017
Scott Dahlbeck officer: Chief Medical Officer 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Americo Cicchetti director 7707 FANNIN, SUITE 140, HOUSTON TX 77054
Gianluca Rotino director, officer: CSIO 7707 FANNIN, SUITE 140, HOUSTON TX 77054

Kiromic BioPharma (Kiromic BioPharma) Headlines

From GuruFocus

Kiromic BioPharma Arranges Up to $10 Million Financing

By Business Wire Business Wire 10-27-2022